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Aim: The aim of this study was to assess the therapeutic effect of intraoperative radiotherapy,
describe the method, and examine the occurrence of side effects and quality of life.
Background: Breast conserving therapy has recently become a standard treatment modality
in  patients with early invasive cancer. Radiotherapy, along with surgery, is an integral part of
such  treatment. The important thing of radiotherapy is to deliver a high dose to the tumour
bed.  One of the methods is the intraoperative radiotherapy.
Materials and methods: The analysis comprised sixty Tis-T2N0-1A breast cancer patients
treated with breast conserving surgery. Patients’ mean age was 57 years (range: 32–73 years).
Intraoperative radiation therapy was delivered in the operating theatre during surgery and
involved a single dose of 10 Gy with an electron beam of 4, 6, 9 or 12 MeV. After that, all
patients were treated with whole breast irradiation. During one year observation photos
and  side effects examination were made.
Results: Physical and imaging examinations performed during a one-year follow-up revealed
no  local or distant relapse and good tolerance of IORT. Acute mild responses to the radiothe-
rapy occurred in 23.3% of patients. Based on the examination, a good and very good cosmetic
effect was found in 78.3%, with 83.3% of patients evaluating their treatment effects in the
same way.
Conclusions: Due to its exceptional physical and radiobiological properties, intraoperativeradiation therapy can be a
operative site in managem
tumour bed.
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Table 2 – Tumour histopathology.
Tumour histopathology (tumour type) No. of patients
Ductal carcinoma 49
Labular carcinoma 4
Mucinous carcinoma 4
Papillary carcinoma 2
Tubular carcinoma 2
margin. With the mammary  gland separated from the sub-
cutaneous tissue, the skin could be drawn away from the108  reports of practical oncology an
1.  Background
Breast cancer is the most prevalent cancer among women
in the world and the most frequent cause of cancer deaths.
Breast conserving therapy has recently become a standard
treatment modality in patients with early invasive breast can-
cer. Radiation therapy, along with surgery, is an integral part
of such treatment. Radiotherapy delivered to the whole breast
remains to be a standard procedure in adjuvant treatment in
breast cancer patients after breast-conserving surgery. Many
studies have conﬁrmed its efﬁcacy in reducing both the risk
of local relapse and breast cancer mortality.1 Radiotherapy is
aimed not only to cover the whole breast with a prescribed
dose, but also to increase irradiation dose to the site of tumour
removal, known as boost. The beneﬁts of delivering an addi-
tional dose to a tumour site have been conﬁrmed by the EORTC
study.2 There are many  methods of delivering a high dose to
the post-operative site: brachytherapy, external beam radio-
therapy (electron or photon) and intraoperative radiotherapy.3
Intra Operative Radiation Therapy (IORT) enables a delivery of
a single dose directly to the post-operative site in the course of
a surgical procedure. The application of IORT allows to avoid a
geographical error, enabling a delivery of a single dose to the
target volume.
2.  Aim
The aim of this study was to assess the therapeutic effect
of intraoperative radiation therapy, describe the treatment
method, and examine the occurrence of early and late reac-
tions to radiation and quality of life, including the cosmetic
effect, in women treated conservatively for low-stage breast
cancer.
3.  Materials  and  methods
The analysis comprised sixty Tis-T2N0-1A breast cancer
patients treated with breast conserving surgery at the Greater
Poland Cancer Centre in the period 2008–2009. Patients’ mean
age was 57 years (range: 32–73 years). The characteristics of
the patients in terms of disease stage and histopathological
evaluation are shown in Tables 1 and 2.
14 patients (23.3%) were managed with post-operative
chemotherapy due to the presence of adverse predictors in
post-operative specimens. Hormonal therapy was also given
to 54 patients (93.3%) due to the presence of oestrogen and
progesterone receptors in the tumours.
Intraoperative radiation therapy was delivered in the oper-
ating theatre during a breast conserving surgery. In the ﬁrst
Table 1 – Sample characteristics.
Tumour size-T feature No. of patients No. of patients
with N+ (N1a)
Tis 3 0
T1b 21 2
T1c 33 6
T2 3 1Fig. 1 – Preparation of the tumour bed.
phase, the surgeon excised a lesion with a margin of healthy
tissues. The histopathologist evaluated the excised tumour
by intraoperative examination and determined clear margins.
In the next stage, some breast tissue was dissected from the
facia of the pectoralis major muscle along a 4–5 cm section
for an aluminium-lead plate (thickness 0.5–1.0 cm,  diame-
ter 5–10 cm)  to be placed there as protection for the organs
at risk (lung, heart, pectoral muscle) – see Figs. 1 and 2.
Mobilised breast tissue of the post-operative site was brought
together over the plate. Depending on the size of the tumour
and healthy tissue margin, a diameter of an applicator was
selected for irradiation to cover the excision site with a 2 cmFig. 2 – View of the aluminium-lead plate under the tissues
of the tumour bed.
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Fig. 3 – Tumour with the clips under the mammograph.
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Fig. 4 – Two ﬁelds technique in the whole breast
teleradiotherapy.rradiated volume by being placed outside the applicator, thus
voiding the risk of its being irradiated.
In the case of clinically impalpable lesions, a radiomarker
 i.e. a technetium isotope emitting low-energy gamma radi-
tion used for marking albumin macroaggregates (Masoll)
hich acted as a carrier – was inserted into the tumour area
nder ultrasound guidance one day before the procedure.
hen, in the course of surgery, the location of the tumour
as determined using a scintillation counter and the tumour
emoved along with a margin of healthy tissue. After delin-
ating the specimen with wires  and clips, it was subjected
o radiological assessment in order to locate the tumour and
et margins (see Fig. 3), then, submitted for intraoperative
istopathological examination.4
Following European recommendations, intraoperative sen-
inel biopsy was performed whenever clinically non-enlarged
xillary lymph nodes were found. The procedure involved a
adiomarker – i.e. technetium isotope emitting low-energy
amma  radiation used for marking the albumin nanocol-
oids (Nanocoll) which acted as a carrier – inserted into the
reolar area before the surgery. Then, the area with the
ighest irradiation was marked on the skin of the axilla by
eans of lymphoscyntygraphy. An incision was made and
 specimen of the lymph node collected for intraoperative
xamination at the site where the highest irradiation was
etected using a manual scintillation counter. The node show-
ng the highest radioactivity was identiﬁed to be a sentinel
ode. After removing the sentinel node, the excision site was
hecked for further possible radioactive nodes using a man-
al gamma radiation detector (the radioactive capture was
ecognised as negative for sentinel node capture <10%). If the
esult of the intraoperative test was negative, the procedure
as terminated after sewing up the surgical wound. If the
esult of the intraoperative test was positive and metastases
ound in the sentinel node, axillary lymphadenectomy was
erformed.5,6
At the Greater Poland Cancer Centre, intraoperative radia-
ion therapy is performed with a Mobetron linear accelerator
enerating megavolt electron radiation. The application of
lectron beam ensures high homogeneity of dose distribution
n the target volume. The planning and radiation processesare conducted in the operating theatre in the course of
surgery, after deﬁning a target volume and placing applica-
tors/collimators into the postoperative wound. Owing to that,
a geographic error in locating a tumour bed can be avoided
and radiotherapy correctly delivered to the patient.
Intraoperative radiation therapy at the Centre involved a
single dose of 10 Gy with an electron beam of 4, 6, 9 or 12 MeV
(66.7% of patients were treated with 6 MeV). Dose was speci-
ﬁed to the reference isodose volume representing 95% of the
prescribed dose. A collimator of 4–6 cm in diameter was used
at an angle of 0–30◦ to deliver a right dose of radiation to a
speciﬁc volume of the post-operative site. In 43.3% of patients
(26), a bolus of 0.5–1 cm was used to obtain a desired dose dis-
tribution in the target volume. The mean depth of irradiated
tissue was 1.97 cm.
After completing the surgical and radiotherapeutic proce-
dures and having received a ﬁnal histopathological results, the
interdisciplinary team for breast cancer patients decided on
further treatment. If so indicated by histopathological results,
patients were given chemotherapy within the ﬁrst stage fol-
lowing surgery with IORT, then whole breast radiation. If
oestrogen and progesterone receptors were found, patients
were given hormonal treatment with 20 mg  of Tamoxifen as
the ﬁrst choice drug administered once per day.
All patients who underwent surgery with IORT  were then
treated with teleradiotherapy. Clinical Target Volume (CTV)
comprised the whole mammary  gland. Radiation was done
using two adjacent beams with energy of 6 MeV  generated in
a Clinac linear accelerator in 25 fractions to a total dose of
50 Gy (Fig. 4).
In the next stage, within a follow-up of at least one year
of the surgery with IORT and in the 1st, 6th and 12th months
after teleradiotherapy, clinical examinations were made and
patients’ breasts photographed. Early and late responses were
analysed using the RTOG/EORTC scale. The patients were also
asked at every visit to complete a quality of life questionnaire
(QLQ-C30) and a breast cancer questionnaire including ques-
tions on the cosmetic effect (QLQ-BR23), as recommended by
RTOG/EORTC. Six months after teleradiotherapy, each patient
was given a mammography and ultrasound examination of
the breast, then mammography control was repeated every 12
months.
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4.  Results
Physical and imaging examinations performed during a
one-year follow-up revealed no local or distant relapse. Intra-
operative radiation therapy was well tolerated. None of the
patients showed any radiation-induced reaction in the skin
immediately after IORT. Five patients developed postopera-
tive haematoma that required surgical drainage. No grade 3
and 4, early or late responses to whole-breast radiation ther-
apy (WBRT) were observed. Acute grade 1 and 2 responses to
WBRT  in the skin occurred in 23.3% patients. The evaluation
of the cosmetic effect 12 months after teleradiotherapy was
each time performed by two radiation therapists. Based on
the physical examination and photo analysis, a good and very
good cosmetic effect was found in 78.3% of the patients.
Questionnaire responses showed 83.3% of patients evalu-
ating their treatment effects as good or very good (12 months
after teleradiotherapy). It has to be borne in mind, how-
ever, that questionnaires reﬂect patients’ subjective opinions,
hence the difference between patients’ evaluations and those
of the therapeutic team (83.3% vs. 78.3%). Pain in the breast
and increased skin susceptibility were reported by 35% of
the patients during follow-up, regardless of the time elapsed
from the end of teleradiotherapy. These conditions occurred
throughout the treated breast. Oedema of the breast was
reported by 14% of the patients 1 month after treatment and
16% of the patients 6 and 12 months after whole-breast radia-
tion therapy. Changes in the breast skin in the form of redness
or visible vascular changes were reported as frequent by 36%
of the patients after 1 month after teleradiotherapy and 22%
in the 6th and 12th months of the follow-up.
5.  Conclusions
1. Intraoperative radiotherapy can replace other methods of
boost in breast conserving therapy.
2. This method is safe and leads to the shortening of therapy
time as compared to electron or photon boost.
3. Radiotherapy boost during surgery not only enables good
local control without geographic miss of the tumour, but
also delivers good cosmetic effect after therapy.
6.  Discussion
Adjuvant radiation therapy of the whole breast following a
breast-conserving surgery remains a commonly recognised
procedure in early stage breast cancer patients. Reports of the
Early Detection of Breast Cancer Group conﬁrm that radiothe-
rapy reduces the risk of local relapse by 75%.1
The impact of radiation dose on reduction of the relapse
rate was, in turn, conﬁrmed by EORTC study 22881-10882
which compared results of treatment and local control for
patients treated with adjuvant radiation versus without a
boost to the post-operative site. The risk of local relapse in
patients who  received a boost dose was reduced from 10.2%
(no boost) to 6.2% (p < 0.0001).7 Therefore, it seems advisable
that a boost dose to the post-operative site be used, apart from
whole breast radiation therapy.iotherapy 1 8 ( 2 0 1 3 ) 107–111
Intraoperative radiation therapy is one of the methods of
delivering a higher dose to the tumour bed in adjuvant treat-
ment of breast cancer patients. This modality allows a precise
irradiation of the post-operative site as radiotherapy is deliv-
ered directly in the course of a surgical procedure. A good
preparation and mobilisation of neighbouring tissue in the
IORT method is a way to avoid geographical error that may
occur with other radiotherapy methods, i.e. brachytherapy or
teleradiotherapy to a selected volume. Owing to intraoperative
radiation therapy, the period of radiation can also be shortened
by one week, i.e. time needed for radiation to the tumour bed
in teleradiotherapy.
The study group showed no local relapse in the breast dur-
ing the one-year follow-up. Similar results have been reported
by other authors.8,9 Yet with the follow-up period being very
short, the result should be looked upon critically and reviewed
again in a further stage of the follow-up.
Our study group did not show any early or late severe
reactions to radiotherapy (grades 3 and 4). Mild early
responses (grades 1 and 2) were found in 23.3% of the
patients, which proved the applied treatment to be safe and
effective. These results are similar to those provided by pub-
lished reports analysing combined IORT with external beam
radiotherapy.8,10–13
While evaluating a new treatment modality, it is not only
the therapeutic effect, manifested with local control and long-
term survival (too early to assess in our study group), that
matters, but also the cosmetic effect. Based on the physical
examination and photo analysis, the cosmetic effect in our
study group was rated as good and very good in 78.3% of the
patients.8,11 This rating was also conﬁrmed by 83.3% of the
patients responding to a questionnaire on cosmetic effect.
With the skin shifted away from the radiation area in the IORT
technique, it was possible to reduce the risk of skin necro-
sis and telangiectasia in the region of the post-operative site.
Treatment with IORT thus proved to be not only a safe modal-
ity that does not involve a higher risk of radiation-induced
complications, but also the one that provides a satisfactory
cosmetic effect.
The analysis of the quality of life and cosmetic effect
questionnaires showed that the patients responded to the
treatment quite well. Intraoperative radiation therapy and
post-surgery external beam radiation did not have a substan-
tial inﬂuence on the quality of life and appearance of the
treated breast.
Due to its exceptional physical and radiobiological proper-
ties, intraoperative radiation therapy can be a good alternative
to other methods of boosting dose to the post-operative site
in management of low stage breast cancer, enabling a precise
therapy to the tumour bed.
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